During the past decade, Rheumatologisches MVZ Dresden GmbH conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rheumatologisches MVZ Dresden GmbH" #1 collaborator was "Hexal AG" with 1 trials as a collaborator and "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Rheumatologisches MVZ Dresden GmbH" are "Rheumatoid Arthritis" (2 trials), "Ankylosing Spondylitis" (1 trials), "Psoriatic Arthritis" (1 trials) and "Rheumatoid Diseases" (1 trials). Many other conditions were trialed in "Rheumatologisches MVZ Dresden GmbH" in a lesser frequency.

Most popular intervention types in "Rheumatologisches MVZ Dresden GmbH" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "CT-P13" (1 trials), "GP2013 - A Proposed biosimilar rituximab" (1 trials) and "Originator rituximab - Rituxan ® or MabThera ®" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rheumatologisches MVZ Dresden GmbH" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Rheumatologisches MVZ Dresden GmbH". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Rheumatologisches MVZ Dresden GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Rheumatologisches MVZ Dresden GmbH, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".